Schnieders Capital Management LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Schnieders Capital Management LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 49.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,498 shares of the company’s stock after buying an additional 7,120 shares during the period. Schnieders Capital Management LLC’s holdings in Novo Nordisk A/S were worth $2,224,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of NVO. Westside Investment Management Inc. increased its holdings in Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after purchasing an additional 649 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $2,408,000. Lazard Asset Management LLC lifted its position in Novo Nordisk A/S by 182.2% during the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after acquiring an additional 964,640 shares in the last quarter. Benedict Financial Advisors Inc. boosted its holdings in Novo Nordisk A/S by 94.0% in the 3rd quarter. Benedict Financial Advisors Inc. now owns 44,292 shares of the company’s stock worth $4,028,000 after acquiring an additional 21,457 shares during the period. Finally, CENTRAL TRUST Co grew its position in Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after acquiring an additional 3,166 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO stock traded up $3.36 during mid-day trading on Tuesday, reaching $128.62. The company had a trading volume of 3,701,385 shares, compared to its average volume of 4,856,259. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The stock has a market capitalization of $577.19 billion, a P/E ratio of 47.55, a P/E/G ratio of 2.05 and a beta of 0.41. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $126.66 and its two-hundred day simple moving average is $111.54.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Research analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is 49.17%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NVO. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.